Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains

Abstract

We have recently shown that oxytocin inhibits cell proliferation when the vast majority of oxytocin receptors are excluded from caveolin-1-enriched microdomains, and that, on the contrary, it has a mitogenic effect when the receptors are targeted to these plasma membrane domains. In this study, we investigated whether the receptors located inside and outside caveolar microdomains initiate different signalling pathways and how this may lead to opposite effects on cell proliferation. Our data indicate that, depending on their localization, oxytocin receptors transactivate EGFR and activate ERK1/2 using different signalling intermediates. The final outcome is a different temporal pattern of EGFR and ERK1/2 phosphorylation, which is more persistent when the receptors are located outside caveolar microdomains and inhibit cell growth, and very transient when they are located in caveolar microdomains and stimulate cell growth. Finally, only the activation of receptors located outside caveolar microdomains correlates with the activation of the cell cycle inhibitor p21WAF1/CIP1, thus suggesting that the antiproliferative OTR effects may, in this case, be achieved by a sustained activation of EGFR and MAPK leading to the induction of this cell cycle regulator.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Adachi T, Kar S, Wang M and Carr BI . (2002). J. Cell Physiol., 192, 151–159.

  • Anderson RG . (1993). Proc. Natl. Acad. Sci. USA, 90, 10909–10913.

  • Breton C, Haenggeli C, Barberis C, Heitz F, Bader CR, Bernheim L and Tribollet E . (2002). J. Clin. Endocrinol. Metab., 87, 1415–1418.

  • Bromberg JF, Fan Z, Brown C, Mendelsohn J and Darnell Jr JE . (1998). Cell Growth Differ., 9, 505–512.

  • Bussolati G and Cassoni P . (2001). Endocrinology, 142, 1130–1136.

  • Carpenter G . (1999). J. Cell Biol., 146, 697–702.

  • Carpenter G . (2000). BioEssays, 22, 697–707.

  • Copland JA, Ives KL, Simmons DJ and Soloff MS . (1999). Endocrinology, 140, 4371–4374.

  • DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD and Bunnett NW . (2000). J. Cell Biol., 148, 1267–1281.

  • Dessy C, Kelly RA, Balligand JL and Feron O . (2000). EMBO J., 19, 4272–4280.

  • Fan Z, Lu Y, Wu X, DeBlasio A, Koff A and Mendelsohn J . (1995). J. Cell Biol., 131, 235–242.

  • Filmus J, Pollak MN, Cailleau R and Buick RN . (1985). Biochem. Biophys. Res. Commun., 128, 898–905.

  • Florio T, Yao H, Carey KD, Dillon TJ and Stork PJ . (1999). Mol. Endocrinol., 13, 24–37.

  • Galbiati F, Razani B and Lisanti MP . (2001). Cell, 106, 403–411.

  • Giles KM, Daly JM, Beveridge DJ, Thomson AM, Voon DC, Furneaux HM, Jazayeri JA and Leedman PJ . (2003). J. Biol. Chem., 278, 2937–2946.

  • Gschwind A, Zwick E, Prenzel N, Leserer M and Ullrich A . (2001). Oncogene, 20, 1594–1600.

  • Gutkind JS . (1998). Oncogene, 17, 1331–1342.

  • Guzzi F, Zanchetta D, Cassoni P, Guzzi V, Francolini M, Parenti M and Chini B . (2002). Oncogene, 21, 1658–1667.

  • Jakus J and Yeudall WA . (1996). Oncogene, 12, 2369–2376.

  • Janes PW, Ley SC, Magee AI and Kabouridis PS . (2000). Semin. Immunol., 12, 23–34.

  • Johannessen LE, Knardal SL and Madshus IH . (1999). Biochem. J., 337 (Part 3), 599–606.

  • Laemmli UK . (1970). Nature, 227, 680–685.

  • Liebmann C . (2001). Cell Signal., 13, 777–785.

  • Ma YC, Huang J, Ali S, Lowry W and Huang XY . (2000). Cell, 102, 635–646.

  • Marshall CJ . (1995). Cell, 80, 179–185.

  • Mineo C, Gill GN and Anderson RG . (1999). J. Biol. Chem., 274, 30636–30643.

  • Moore JJ, Dubyak GR, Moore RM and Kooy DV . (1988). Endocrinology, 123, 1771–1777.

  • Oh P and Schnitzer JE . (2001). Mol. Biol. Cell, 12, 685–698.

  • Okamoto T, Schlegel A, Scherer PE and Lisanti MP . (1998). J. Biol. Chem., 273, 5419–5422.

  • Paquin J, Danalache BA, Jankowski M, McCann SM and Gutkowska J . (2002). Proc. Natl. Acad. Sci. USA, 99, 9550–9555.

  • Phaneuf S, Europe-Finner GN, Varney M, MacKenzie IZ, Watson SP and Lopez Bernal A . (1993). J. Endocrinol, 136, 497–509.

  • Pierce KL, Luttrell LM and Lefkowitz RJ . (2001). Oncogene, 20, 1532–1539.

  • Prenzel N, Fischer OM, Streit S, Hart S and Ullrich A . (2001). Endocr. Relat. Cancer, 8, 11–31.

  • Roovers K and Assoian RK . (2000). BioEssays, 22, 818–826.

  • Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR and Anderson RG . (1992). Cell, 68, 673–682.

  • Rybin VO, Xu X, Lisanti MP and Steinberg SF . (2000). J. Biol. Chem., 275, 41447–41457.

  • Sanborn BM . (2001). Exp. Physiol., 86, 223–237.

  • Simons K and Toomre D . (2000). Nat. Rev. Mol. Cell. Biol., 1, 31–39.

  • Sorkin A and Von Zastrow M . (2002). Nat. Rev. Mol. Cell. Biol., 3, 600–614.

  • Strakova Z and Soloff MS . (1997). Am. J. Physio., 272, E870–E876.

  • Thibonnier M, Conarty DM, Preston JA, Plesnicher CL, Dweik RA and Erzurum SC . (1999). Endocrinology, 140, 1301–1309.

  • Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK and Alexander RW . (2001). J. Biol. Chem., 3, 3.

  • Volmat V and Pouyssegur J . (2001). Biol. Cell, 93, 71–79.

  • Xie W, Su K, Wang D, Paterson AJ and Kudlow JE . (1997). Anticancer Res., 17, 2627–2633.

Download references

Acknowledgements

We thank Dr L Vallar (University of Milan, Italy) for helpful suggestions and discussions and Prof GE Rovati (University of Milan, Italy) for providing several chemicals. This work was supported by MIUR grants (Cofin 2000 and Cofin 2002) to MP.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bice Chini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rimoldi, V., Reversi, A., Taverna, E. et al. Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene 22, 6054–6060 (2003). https://doi.org/10.1038/sj.onc.1206612

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206612

Keywords

This article is cited by

Search

Quick links